A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Inclusion Criteria: Participant must:

• Have been diagnosed with type 2 diabetes mellitus based on the World HealthOrganization classification before the screening visit.
• Have HbA1c ≥7.0% to <11.0%, as determined by the central laboratory at screening.
• Have been taking sulfonylureas, biguanides, thiazolidinedione, alpha-glucosidaseinhibitor, glinides, or sodium-glucose cotransporter type 2 inhibitor monotherapy forat least 3 months before screening and have been on the following dose for at least 8weeks before screening.
• Have body mass index (BMI) of ≥23 kilograms per meter squared at screening.
• Be of stable weight (±5%) during 3 months preceding screening; and agree to notinitiate an intensive diet and/or exercise program during the study with the intent ofreducing body weight other than the lifestyle and dietary measures for diabetestreatment.

Exclusion Criteria: Participant must not:

• Have type 1 diabetes mellitus.
• Have had chronic or acute pancreatitis any time prior to study entry.
• Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferativediabetic retinopathy requiring immediate or urgent treatment.
• Have disorders associated with slowed emptying of the stomach, or have had any stomachsurgeries for the purpose of weight loss.
• Have acute or chronic hepatitis, signs and symptoms of any other liver disease, orblood alanine transaminase (ALT) enzyme level >3.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory. Participantswith nonalcoholic fatty liver disease (NAFLD) are eligible for participation in thistrial only if there ALT level is ≤3.0 the ULN for the reference range.
• Have had a heart attack, stroke, or hospitalization for congestive heart failure inthe past 2 months.
• Have a personal or family history of medullary thyroid carcinoma or personal historyof multiple endocrine neoplasia syndrome type 2.
• Have been taking weight loss drugs, including over-the-counter medications during thelast 3 months.